A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

This is an early-phase (Phase I) safety study of a new experimental drug called ETH-155008 in people with certain blood cancers — specifically acute myeloid leukemia (AML) or non-Hodgkin's lymphoma (NHL) — whose cancer has come back or stopped responding to standard treatments. **You may be eligible if...** - You are 18–79 years old - You have been diagnosed with relapsed or treatment-resistant AML or certain types of NHL (including follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, or others) - You have already tried at least 2 prior treatment regimens (requirements vary by cancer type) - Standard treatment options are no longer available or suitable for you **You may NOT be eligible if...** - You have a history of serious heart conditions or severe organ problems - You have active autoimmune disease or uncontrolled infection - You have received stem cell transplant recently or have serious liver/kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.